<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02835586</url>
  </required_header>
  <id_info>
    <org_study_id>2011-701</org_study_id>
    <nct_id>NCT02835586</nct_id>
  </id_info>
  <brief_title>STREAMER : STent Restenosis And MEdicaments Release</brief_title>
  <acronym>STREAMER</acronym>
  <official_title>STREAMER : Stent Restenosis and Medicaments Release : Does Local Delivery of Paclitaxel be Safe and Efficient in Stenting of TransAtlantic InterSociety Consensus (TASC) Class C and D Femoropopliteal Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a pilot study to evaluate the feasibility and the efficiency of local delivery of
      paclitaxel after stenting of long femoropopliteal arterial lesions TASC C and D before the
      realization of a large randomized multicentric study. Patients concerned are in critical
      ischemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with femoropopliteal artery restenosis</measure>
    <time_frame>12 months</time_frame>
    <description>defined as restenosis &gt; 50 % with a velocity pick &gt; 2,5 on duplex ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurence of adverse events due to paclitaxel</measure>
    <time_frame>From1 day to 12 months</time_frame>
    <description>biological adverse events (thrombopenia, neutropenia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with target lesion revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>number of subjects who need a new revascularization on the same artery (femoropopliteal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of amputation free-survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulated rate of morbi-mortality (TCMM)</measure>
    <time_frame>up to 30 days</time_frame>
    <description>myocardial infarction, death, vascular ischemic accident, cardiac angina, major amputation, new hospitalization or new surgery for hematoma, thrombosis or false aneurysm</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Critical Ischemia</condition>
  <arm_group>
    <arm_group_label>paclitaxel delivery in femoropopliteal artery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery and/or popliteal artery after stenting. Dosing will be based on the lesion surface area and will be calculated using the following formula : 22/7 x diameter (mm) x length (mm) x 3 Âµg/mm3</description>
    <arm_group_label>paclitaxel delivery in femoropopliteal artery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with critical ischemia of a lower limb with ankle pressure &lt; 50 mmHg

          -  lesions TASC C and D of the superficial femoral or popliteal artery

        Exclusion Criteria:

          -  patient allergic to paclitaxel

          -  patient with a cancer, a neutropenia, with immunosuppressor medicament or chemotherapy

          -  patient with contraindication to take 2 anti-aggregants platelets
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nellie DELLA SCHIAVA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>department of vascular surgery, Edouard Herriot Hospital, LYON</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>department of vascular surgery, Edouard Herriot Hospital, 5 Place d'Arsonval</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2016</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>paclitaxel</keyword>
  <keyword>critical ischemia</keyword>
  <keyword>restenosis</keyword>
  <keyword>femoropopliteal artery lesions TASC C and D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

